[{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"da630ed2-aba8-4d08-84f9-a31e25b0efa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06527495","created_at":"2025-02-27T07:56:52.092Z","updated_at":"2025-02-27T07:56:52.092Z","phase":"Phase 1/2","brief_title":"Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT06527495","lead_sponsor":"Assiut University","biomarkers":" KDR • VEGFA","pipe":"","alterations":" ","tags":["KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-07-30"},{"id":"3dd7c2f3-5edb-4afd-aab6-f0b5ef867dad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796273","created_at":"2021-01-18T18:46:15.719Z","updated_at":"2024-07-02T16:35:11.784Z","phase":"Phase 1","brief_title":"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03796273","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" KDR • CD24 • POU5F1 • VEGFC","pipe":"","alterations":" ","tags":["KDR • CD24 • POU5F1 • VEGFC"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-03"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"369a58dd-4a69-448b-9669-35759434dc53","acronym":"TWICE-IRI","url":"https://clinicaltrials.gov/study/NCT04392479","created_at":"2021-01-18T21:11:59.050Z","updated_at":"2024-07-02T16:35:32.165Z","phase":"Phase 3","brief_title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","source_id_and_acronym":"NCT04392479 - TWICE-IRI","lead_sponsor":"GCS IHFB Cognacq-Jay","biomarkers":" KDR • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-23"},{"id":"74d0474d-8a4d-4196-856a-9f95d19d924e","acronym":"BIOVAS","url":"https://clinicaltrials.gov/study/NCT04072042","created_at":"2021-01-18T19:56:06.263Z","updated_at":"2024-07-02T16:35:35.004Z","phase":"Phase 2","brief_title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma","source_id_and_acronym":"NCT04072042 - BIOVAS","lead_sponsor":"Ruijin Hospital","biomarkers":" KDR • CSF1R","pipe":"","alterations":" ","tags":["KDR • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 02/25/2024","primary_completion_date":" 02/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2023-10-03"},{"id":"422ad72d-7a97-443d-a2f9-20594b17c5fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01253213","created_at":"2021-01-18T05:03:06.361Z","updated_at":"2024-07-02T16:35:41.488Z","phase":"Phase 1","brief_title":"BR55 in Prostate Cancer: an Exploratory Clinical Trial","source_id_and_acronym":"NCT01253213","lead_sponsor":"Bracco Diagnostics, Inc","biomarkers":" KDR","pipe":" | ","alterations":" KDR expression","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2023-08-01"},{"id":"bf5a06b8-9332-4fc0-b6bc-7ab5329ddba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01048918","created_at":"2021-01-18T04:07:15.273Z","updated_at":"2024-07-02T16:35:43.930Z","phase":"","brief_title":"Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer","source_id_and_acronym":"NCT01048918","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • HER-2 • ER • KDR","pipe":"","alterations":" ","tags":["EGFR • HER-2 • ER • KDR"],"overall_status":"Completed","enrollment":" Enrollment 280","initiation":"Initiation: 09/04/2008","start_date":" 09/04/2008","primary_txt":" Primary completion: 04/08/2022","primary_completion_date":" 04/08/2022","study_txt":" Completion: 04/08/2022","study_completion_date":" 04/08/2022","last_update_posted":"2023-07-04"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"c865fa8d-eedd-4411-807c-9590facd411f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05591560","created_at":"2022-10-24T13:56:57.884Z","updated_at":"2024-07-02T16:36:01.977Z","phase":"","brief_title":"Itraconazole in Advanced Ovarian Cancer","source_id_and_acronym":"NCT05591560","lead_sponsor":"Tanta University","biomarkers":" KDR • MUC16","pipe":"","alterations":" ","tags":["KDR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • itraconazole"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-10-24"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"2b254b65-c6b8-4df3-bdd4-baa535365a6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03878472","created_at":"2021-01-18T19:07:14.827Z","updated_at":"2024-07-02T16:36:13.787Z","phase":"Phase 2","brief_title":"Neoadjuvant Immunotherapy for Resectable Gastric Cancer","source_id_and_acronym":"NCT03878472","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-04-07"},{"id":"ae1e8c24-b294-4351-8115-ef1d4ef0a78a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04018872","created_at":"2021-11-04T14:52:58.385Z","updated_at":"2024-07-02T16:36:21.182Z","phase":"Phase 2","brief_title":"Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer","source_id_and_acronym":"NCT04018872","lead_sponsor":"Dallas VA Medical Center","biomarkers":" KDR • GLI1 • GLI3 • GLI2 • SHH","pipe":" | ","alterations":" GLI3 expression","tags":["KDR • GLI1 • GLI3 • GLI2 • SHH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/24/2026","primary_completion_date":" 06/24/2026","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2021-11-04"},{"id":"7c346db6-4174-4292-8a2b-5cb3e58e0611","acronym":"","url":"https://clinicaltrials.gov/study/NCT05105464","created_at":"2021-11-03T12:53:05.612Z","updated_at":"2024-07-02T16:36:21.590Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05105464","lead_sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","biomarkers":" PD-L1 • FGFR • KDR • CEACAM5 • FGF23","pipe":"","alterations":" ","tags":["PD-L1 • FGFR • KDR • CEACAM5 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SYHA1815"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-11-03"},{"id":"5952600c-1558-48e1-9ded-cd63c4250110","acronym":"LOLA","url":"https://clinicaltrials.gov/study/NCT04427787","created_at":"2021-03-16T19:52:54.538Z","updated_at":"2024-07-02T16:36:24.800Z","phase":"Phase 2","brief_title":"A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET","source_id_and_acronym":"NCT04427787 - LOLA","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" AXL • KDR • SSTR2","pipe":"","alterations":" ","tags":["AXL • KDR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2021-09-06"},{"id":"81732a4f-3390-49ea-a156-28fdbac06dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02133742","created_at":"2021-01-18T09:54:06.406Z","updated_at":"2024-07-02T16:36:27.343Z","phase":"Phase 1b","brief_title":"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer","source_id_and_acronym":"NCT02133742","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • mTOR • KDR • CXCL8 • FLT1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • mTOR • KDR • CXCL8 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 09/16/2014","start_date":" 09/16/2014","primary_txt":" Primary completion: 03/31/2017","primary_completion_date":" 03/31/2017","study_txt":" Completion: 07/03/2019","study_completion_date":" 07/03/2019","last_update_posted":"2021-07-28"},{"id":"f76845b1-ea5c-4ee7-9b14-d75b2ede7244","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514123","created_at":"2021-01-18T06:21:50.486Z","updated_at":"2024-07-02T16:36:40.929Z","phase":"Phase 1","brief_title":"Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01514123","lead_sponsor":"Circadian Technologies Ltd.","biomarkers":" KDR • FLT4 • VEGFD • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFD • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/29/2011","start_date":" 12/29/2011","primary_txt":" Primary completion: 02/07/2014","primary_completion_date":" 02/07/2014","study_txt":" Completion: 11/16/2017","study_completion_date":" 11/16/2017","last_update_posted":"2020-09-17"},{"id":"863fe75f-2ea4-42b9-b212-5a3e91bd2364","acronym":"","url":"https://clinicaltrials.gov/study/NCT04548271","created_at":"2021-01-18T21:44:42.961Z","updated_at":"2024-07-02T16:36:41.059Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04548271","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • KDR","pipe":" | ","alterations":" PD-L1 expression • KDR expression","tags":["PD-L1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KDR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-09-14"},{"id":"eee50566-4809-4235-980c-428fc0234dc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04547088","created_at":"2021-01-18T21:45:03.608Z","updated_at":"2024-07-02T16:36:41.063Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04547088","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • KDR","pipe":" | ","alterations":" PD-L1 expression • KDR expression","tags":["PD-L1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KDR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-09-14"},{"id":"265c0e3a-402e-40b9-8f6d-dbb577309908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03658070","created_at":"2021-01-18T17:57:09.129Z","updated_at":"2024-07-02T16:36:41.784Z","phase":"Phase 1","brief_title":"A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT03658070","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XY0206"],"overall_status":"Unknown status","enrollment":" Enrollment 34","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-08-21"},{"id":"931a0803-d4c8-4f98-9bb6-97e87c40e482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01956669","created_at":"2021-01-18T08:52:55.254Z","updated_at":"2024-07-02T16:36:42.063Z","phase":"Phase 2","brief_title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","source_id_and_acronym":"NCT01956669","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • KDR • AFP • FLT1 • VEGFC • FGF","pipe":"","alterations":" ","tags":["KIT • KDR • AFP • FLT1 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2020-08-12"},{"id":"9b88c18b-5dbc-410e-baed-d090e5a3cd6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446809","created_at":"2021-01-18T06:00:08.601Z","updated_at":"2024-07-02T16:36:46.074Z","phase":"","brief_title":"Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT01446809","lead_sponsor":"University of Washington","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-04-13"},{"id":"d6d64b89-f7f7-4bec-a903-6fffbe1ea5b6","acronym":"DISTINCTIVE","url":"https://clinicaltrials.gov/study/NCT04252456","created_at":"2021-01-18T20:39:55.170Z","updated_at":"2024-07-02T16:36:50.523Z","phase":"","brief_title":"Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status","source_id_and_acronym":"NCT04252456 - DISTINCTIVE","lead_sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","biomarkers":" KDR • RAS • FLT4 • IL1A","pipe":" | ","alterations":" RAS wild-type","tags":["KDR • RAS • FLT4 • IL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 04/23/2018","start_date":" 04/23/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2020-02-05"}]